BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Rapporto sulle azioni

Cap. di mercato: US$13.4b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BioMarin Pharmaceutical Dividendo

Dividendo criteri di controllo 0/6

BioMarin Pharmaceutical non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore1.9%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azioneUS$1.35
Previsione del rendimento del dividendo0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

Sep 21
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

Jul 24

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Mar 30
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05
Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Dec 15
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Nov 03
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Aug 09
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Jul 18
We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18
Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27
These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25
Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BMRN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BMRN siano aumentati.

Rendimento dei dividendi rispetto al mercato

BioMarin Pharmaceutical Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di BMRN rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (BMRN)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.3%
Media del settore (Biotechs)1.9%
Analista previsionale (BMRN) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BMRN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BMRN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BMRN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BMRN non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

7D

1Y

7D

1Y

7D

1Y